Ash 2025 Congress Coverage Phase Iii Clinical Trials In Aml Catch up with our live social media coverage of the latest developments from phase iii clinical trials in acute myeloid leukemia from the 67th american society of hematology (ash) annual meeting and exposition, december 6–9, 2025, orlando, us. The following summaries highlight key findings from research posters presented at the 67th ash annual meeting, showcasing new developments in oral maintenance therapies for acute myeloid leukemia (aml).
Ash Hematology Review Series Aml Sallman D 6 2022 Pdf The promising results of two clinical trials led by eunice wang, md, chief of leukemia at roswell park comprehensive cancer center, suggest that combining targeted inhibitors with chemotherapy could induce clinical responses in 60 80% of aml patients with relapsed aggressive subtypes of the disease and prolong overall survival. The myelomatch screening trial and five treatment trials of targeted combination agents are open for patient enrollment, with more treatment trials planned. Explore top ash 2025 abstracts analyzed by ferma congress key data on aml, mm, scd, lymphomas, and mds shaping the future of hematology research. Explore expert presentations & discussions from the post ash 2025 aml webinar hosted by vjhemonc, covering key acute myeloid leukemia updates.
Ash 2025 Annual Meeting Explore top ash 2025 abstracts analyzed by ferma congress key data on aml, mm, scd, lymphomas, and mds shaping the future of hematology research. Explore expert presentations & discussions from the post ash 2025 aml webinar hosted by vjhemonc, covering key acute myeloid leukemia updates. At the american society of hematology’s 67th annual meeting in orlando dec. 6, researcher jesse tettero presented data supporting the use of a measurable residual disease (mrd) surrogate endpoint in acute myeloid leukemia (aml) research. Abstracts for the 2025 ash annual meeting and exposition, including late breaking abstracts, are now available. a record breaking number of abstracts were submitted and more than 8,200 were accepted. Researchers from mass general brigham cancer institute will present research discoveries and outcomes from clinical trials in hematology oncology, including cancer and common blood disorders, at the 2025 american society of hematology (ash) annual meeting, held december 6–9, in orlando. Acute myeloid leukemia (aml) research presented at the ash annual 2025 meeting evaluates the supportive role of dexamethasone in consolidation therapy for younger adults with aml, provides new insights into minimum residual disease (mrd) adaptive treatment in adult aml, and highlights opportunities to spare pediatric patients with aml from some.
Ash 2025 Annual Meeting At the american society of hematology’s 67th annual meeting in orlando dec. 6, researcher jesse tettero presented data supporting the use of a measurable residual disease (mrd) surrogate endpoint in acute myeloid leukemia (aml) research. Abstracts for the 2025 ash annual meeting and exposition, including late breaking abstracts, are now available. a record breaking number of abstracts were submitted and more than 8,200 were accepted. Researchers from mass general brigham cancer institute will present research discoveries and outcomes from clinical trials in hematology oncology, including cancer and common blood disorders, at the 2025 american society of hematology (ash) annual meeting, held december 6–9, in orlando. Acute myeloid leukemia (aml) research presented at the ash annual 2025 meeting evaluates the supportive role of dexamethasone in consolidation therapy for younger adults with aml, provides new insights into minimum residual disease (mrd) adaptive treatment in adult aml, and highlights opportunities to spare pediatric patients with aml from some.
Comments are closed.